Incyte gears up to face FDA once again with more Zynyz data in rare anal cancer

Ayisha Sharma

News Reporter

BARCELONA — Incyte said it has positive late-stage results for its PD-1 drug Zynyz in certain patients with squamous cell carcinoma, three years after the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Incyte gears up to face FDA once again with more Zynyz data in rare anal cancer

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

All of 23andMe's independent board members resign over disagreements with CEO

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

Bad trip: How culture conflict and a need for cash nearly broke Lykos

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Breaking down silos with a new quantitative approach to drug development

In­cyte gears up to face FDA once again with more Zynyz da­ta in rare anal can­cer

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Incyte gears up to face FDA once again with more Zynyz data in rare anal cancer